Classification of loratadine based on the biopharmaceutics drug classification concept and possible in Vitro-in Vivo correlation

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 10, 2004, Pages 1630-1635

  Khan, M Zahirul I ^a   Raušl, Dragica ^a   Zanoški, Ružica ^a   Zidar, Snježana ^a   Mikulčić, Jasna Horvat ^a,b   Krizmanić, Lara ^a   Eškinja, Maja ^a,c   Mildner, Boris ^a   Knězević, Zdravka ^a  

^a PLIVA Research Institute Ltd   (Croatia)

^b Veterinarska Stanica Čakovec ^*  (Croatia)

^c Technology Improvement Product Supply   (Croatia)

Author keywords

Biopharmaceutics classification system; Biorelevant dissolution testing; Convolution; In vitro in vivo correlation; IVIVC; Loratadine; Permeability testing

Indexed keywords

LORATADINE;

ANALYTIC METHOD; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG RELEASE; DRUG SOLUBILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYDRODYNAMICS; INTESTINE FLUID; NORMAL HUMAN; PH; PLASMA; STOMACH PH; SYRUP; TABLET; AREA UNDER THE CURVE; BIOAVAILABILITY; CHEMISTRY; CLASSIFICATION; CLINICAL TRIAL; MALE; PERMEABILITY; PHARMACEUTICS; SOLUBILITY;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOPHARMACEUTICS; CACO-2 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; LORATADINE; MALE; PERMEABILITY; SOLUBILITY;

EID: 21644477111     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.1630     Document Type: Article

References (19)

1. Hilbert J., Radwanski E., Weglein R., Luc V., Perentesis G., Symchowicz S., Zampaglione N., J. Clin. Pharmacol., 27, 694-698 (1987).
2. Katchen B., Cramer J., Chung M., Ann. Allergy, 55, 393 (1985).
3. Radwanski E., Hilbert J., Symchowicz S., Zampaglione N., J. Clin. Pharmacol., 27, 530-533 (1987).
4. Amidon G. L., Lennernäs H., Shah V. P., Crison J. R., Pharm. Res., 12, 413-420 (1995).
5. CDER, Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid dosage forms based on Biopharmaceutics Classification System. Rockville: FDA. (August 2000).
6. Kaliszan R., Nasal A., Turowski M., Biomed. Chromatogr., 9, 211-215 (1995).
7. cited in: Gao J. G., Hugger E. D., Beck-Westernmeyer M. S., Borchart R. T., "Estimating intestinal mucosal permeation of compounds using Caco-2 cell monolayers," "Current Protocols in Pharmacology," ed. by Enna S. J., Williams M., Ferkany J. W., Kenakin T., Porsolt R. D., Sullivan J. P., John Wiley & Sons, Inc., New York, 2000, pp. 7.2.1.-7.2.23.
8. Galia E., Nicolaides E., Hörter D., Löbenberg R., Reppas C., Dressman J. B., Pharm. Res., 15, 698-705 (1998).
9. Grès M.-C., Julian B., Bourrié M., Meunier V., Roques C., Berger M., Boulenc X., Berger Y., Fabre G., Pharm. Res., 15, 726-733 (1998).
10. Rege B. D., Yu L. X., Hussain A. S., Polli J. E., J. Pharm. Sci., 90, 1776-1786 (2001).
11. Polli J. W., Wring S. A., Humphreys J. E., Huang L., Morgan J. B., Webster L. O., Serabjit-Singh C. S., J. Pharmacol. Exp. Ther., 299, 620-628 (2001).
12. Lentz K. A., Polli J. W., Wring S. A., Humphreys J. E., Polli J. E., Pharm. Res., 17, 1456-1460 (2000).
13. Lee K., Chee N., Brouwer K. L. R., Thakker D. R., J. Pharmacol. Exp. Ther., 303, 574-580 (2002).
14. Galia E., Horton J., Dressman J. B., Pharm. Res., 16, 1871-1875 (1999).
15. Evans D. F., Pye G., Bramley R., Clark A. G., Dyson T. J., Hardcastle J. D., Gut, 29, 1035-1041 (1988).
16. Dressman J. B., Amidon G. L., Reppas C., Shah V. P., Pharm. Res., 15, 11-22 (1998).
17. cited in: Golub A. L., Frost R. W., Betlach C. J., Gonzalez M. A., J. Allergy Clin. Immunol., 78, 689-694 (1986).
18. Langenbucher F., Pharm. Ind., 44, 1166-1172 (1982).
19. Kostewicz E. S., Brauns U., Becker R., Dressman J. B., Pharm. Res., 19, 345-349 (2002).